|
Overview
Chronic obstructive pulmonary disease (COPD) is one of the most common lung diseases. It is a progressive disease that is manifested by difficulty in breathing due to lung damage and heart failure. There are two main forms of COPD:
- Chronic bronchitis, defined by a long-term cough marked by bronchoconstriction, inflammation and changes to the airways that result in increased mucus production
- Emphysema, defined by destruction of the lungs over time
Most people with COPD have a combination of both chronic bronchitis and emphysema and more than 85% of the disease is attributed to cigarette smoking.
INV102 for COPD
INV102 shows early promise to reverse mucous metaplasia in models of COPD, thereby treating cough, sputum production and reducing the risk of infection. In addition, long-term treatment with the drug has potential to restore normal airway cell population (ciliated bronchial epithelium). Moreover, published data on the use of beta-blockers (non selective inverse agonists) in patients with chronic heart failure and COPD has consistently shown a reduction in rate and severity of exacerbations (hospitalization, Emergency Department visits).
Inverseon is developing INV102 (nadolol) for the long-term treatment of chronic bronchitis, to reduce sign and symptoms, frequency and severity of infection and the risk and severity of exacerbation in patients with COPD. INV102 is presently administered orally and is being developed for dosing by inhalation, either alone or in combination with other medications used to treat COPD. INV102 is expected to complement low-dose inhaled corticosteroids and improve the efficacy and safety of long acting beta agonists and anticholinergics.
|
